Bone targeting agents in patients with prostate cancer: general toxicities and osteonecrosis of the jaw
Last Updated: Friday, July 17, 2026
This literature review spotlights the role of bone-targeted agents in the treatment of hormone-sensitive and castration-resistant prostate cancer–related bone metastases, including associated adverse events and osteonecrosis of the jaw.
